|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HSD17B11 |
Gene summary for HSD17B11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HSD17B11 | Gene ID | 51170 |
| Gene name | hydroxysteroid 17-beta dehydrogenase 11 | |
| Gene Alias | 17-BETA-HSD11 | |
| Cytomap | 4q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q8NBQ5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51170 | HSD17B11 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.77e-11 | -5.96e-01 | 0.0155 |
| 51170 | HSD17B11 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.92e-04 | 3.76e-01 | -0.1954 |
| 51170 | HSD17B11 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.65e-02 | -3.63e-01 | -0.1464 |
| 51170 | HSD17B11 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.52e-06 | -4.30e-01 | 0.096 |
| 51170 | HSD17B11 | HTA11_10711_2000001011 | Human | Colorectum | AD | 8.07e-05 | -5.82e-01 | 0.0338 |
| 51170 | HSD17B11 | HTA11_7696_3000711011 | Human | Colorectum | AD | 6.67e-13 | -4.76e-01 | 0.0674 |
| 51170 | HSD17B11 | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.44e-04 | -5.47e-01 | 0.0588 |
| 51170 | HSD17B11 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.28e-06 | -4.17e-01 | 0.294 |
| 51170 | HSD17B11 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.72e-04 | -6.55e-01 | 0.2585 |
| 51170 | HSD17B11 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 7.31e-16 | -6.07e-01 | 0.3005 |
| 51170 | HSD17B11 | F007 | Human | Colorectum | FAP | 1.06e-06 | -5.84e-01 | 0.1176 |
| 51170 | HSD17B11 | A002-C-010 | Human | Colorectum | FAP | 4.12e-04 | -4.21e-01 | 0.242 |
| 51170 | HSD17B11 | A001-C-207 | Human | Colorectum | FAP | 1.21e-08 | -5.45e-01 | 0.1278 |
| 51170 | HSD17B11 | A015-C-203 | Human | Colorectum | FAP | 2.00e-26 | -4.95e-01 | -0.1294 |
| 51170 | HSD17B11 | A015-C-204 | Human | Colorectum | FAP | 1.21e-09 | -5.32e-01 | -0.0228 |
| 51170 | HSD17B11 | A014-C-040 | Human | Colorectum | FAP | 2.90e-03 | -4.38e-01 | -0.1184 |
| 51170 | HSD17B11 | A002-C-201 | Human | Colorectum | FAP | 1.35e-16 | -5.73e-01 | 0.0324 |
| 51170 | HSD17B11 | A002-C-203 | Human | Colorectum | FAP | 3.52e-14 | -5.23e-01 | 0.2786 |
| 51170 | HSD17B11 | A001-C-119 | Human | Colorectum | FAP | 3.64e-06 | -4.35e-01 | -0.1557 |
| 51170 | HSD17B11 | A001-C-108 | Human | Colorectum | FAP | 4.02e-19 | -4.80e-01 | -0.0272 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
| GO:0016042 | Colorectum | AD | lipid catabolic process | 97/3918 | 320/18723 | 4.31e-05 | 7.56e-04 | 97 |
| GO:0008202 | Colorectum | AD | steroid metabolic process | 85/3918 | 319/18723 | 8.07e-03 | 4.75e-02 | 85 |
| GO:19013612 | Colorectum | MSS | organic cyclic compound catabolic process | 148/3467 | 495/18723 | 3.47e-10 | 3.18e-08 | 148 |
| GO:00160422 | Colorectum | MSS | lipid catabolic process | 77/3467 | 320/18723 | 7.43e-03 | 4.71e-02 | 77 |
| GO:19013614 | Colorectum | FAP | organic cyclic compound catabolic process | 101/2622 | 495/18723 | 4.87e-05 | 9.93e-04 | 101 |
| GO:00160423 | Colorectum | FAP | lipid catabolic process | 65/2622 | 320/18723 | 1.13e-03 | 1.08e-02 | 65 |
| GO:19013615 | Colorectum | CRC | organic cyclic compound catabolic process | 80/2078 | 495/18723 | 3.52e-04 | 5.34e-03 | 80 |
| GO:00160424 | Colorectum | CRC | lipid catabolic process | 53/2078 | 320/18723 | 1.89e-03 | 1.93e-02 | 53 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:00066946 | Esophagus | ESCC | steroid biosynthetic process | 98/8552 | 173/18723 | 2.34e-03 | 1.03e-02 | 98 |
| GO:00160427 | Esophagus | ESCC | lipid catabolic process | 168/8552 | 320/18723 | 7.97e-03 | 2.84e-02 | 168 |
| GO:190136111 | Liver | Cirrhotic | organic cyclic compound catabolic process | 213/4634 | 495/18723 | 1.58e-19 | 3.67e-17 | 213 |
| GO:000820211 | Liver | Cirrhotic | steroid metabolic process | 143/4634 | 319/18723 | 2.79e-15 | 3.18e-13 | 143 |
| GO:00066941 | Liver | Cirrhotic | steroid biosynthetic process | 77/4634 | 173/18723 | 1.02e-08 | 3.91e-07 | 77 |
| GO:001604212 | Liver | Cirrhotic | lipid catabolic process | 112/4634 | 320/18723 | 2.31e-05 | 3.03e-04 | 112 |
| GO:00082101 | Liver | Cirrhotic | estrogen metabolic process | 18/4634 | 38/18723 | 2.05e-03 | 1.27e-02 | 18 |
| GO:004244511 | Liver | Cirrhotic | hormone metabolic process | 73/4634 | 218/18723 | 2.22e-03 | 1.36e-02 | 73 |
| GO:0008209 | Liver | Cirrhotic | androgen metabolic process | 15/4634 | 30/18723 | 2.45e-03 | 1.47e-02 | 15 |
| GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HSD17B11 | insertion | Nonsense_Mutation | novel | c.326_327insCTACCTTGTGTGTGAGATTTCTTACCCTGTCTAATA | p.Ala109_Glu110insTyrLeuValCysGluIleSerTyrProValTerTer | p.A109_E110insYLVCEISYPV** | Q8NBQ5 | protein_coding | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| HSD17B11 | deletion | Frame_Shift_Del | novel | c.48delN | p.Cys17AlafsTer3 | p.C17Afs*3 | Q8NBQ5 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| HSD17B11 | SNV | Missense_Mutation | c.140G>C | p.Gly47Ala | p.G47A | Q8NBQ5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| HSD17B11 | SNV | Missense_Mutation | c.442N>T | p.His148Tyr | p.H148Y | Q8NBQ5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| HSD17B11 | SNV | Missense_Mutation | novel | c.193N>A | p.Leu65Ile | p.L65I | Q8NBQ5 | protein_coding | deleterious(0) | possibly_damaging(0.809) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| HSD17B11 | SNV | Missense_Mutation | novel | c.315G>T | p.Lys105Asn | p.K105N | Q8NBQ5 | protein_coding | tolerated(0.22) | benign(0.054) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HSD17B11 | deletion | Frame_Shift_Del | c.9delT | p.Leu4PhefsTer11 | p.L4Ffs*11 | Q8NBQ5 | protein_coding | TCGA-A6-A566-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | PD | |||
| HSD17B11 | insertion | Nonsense_Mutation | novel | c.831_832insAAACATTAAAATT | p.Leu278LysfsTer3 | p.L278Kfs*3 | Q8NBQ5 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| HSD17B11 | SNV | Missense_Mutation | novel | c.799N>G | p.Thr267Ala | p.T267A | Q8NBQ5 | protein_coding | tolerated(0.06) | benign(0.023) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HSD17B11 | SNV | Missense_Mutation | rs562443434 | c.896C>T | p.Ala299Val | p.A299V | Q8NBQ5 | protein_coding | tolerated(0.28) | benign(0.001) | TCGA-A5-A7WJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |